DeepMed Research

Shanghai Hengrui Pharmaceutical Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: Subsidiary

Established: 2001-12-04

Employees: -

Market Cap: -

Website: http://www.shhrp.com

Clinical Trials

Phase Ⅱ Study of Adductor Canal Block With HR18034 for Postsurgical Pain Management in TKA

Phase 2

Terminated

Conditions: Postoperative Pain Management in Total Knee Arthroplasty

Interventions: Drug: Ropivacaine Hydrochloride Injection
Drug: HR18034

First Posted Date: 2024-07-19

Last Posted Date: 2024-10-30

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 15

Registration Number: NCT06509958

Locations: 🇨🇳
Tianjin Medical University General Hospital, Tianjin, Tianjin, China

A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer

Phase 1

Recruiting

Conditions: Advanced or Metastatic Esophageal Cancer

Interventions: Drug: SHR-A2102；Adebrelimab；Cisplatin

First Posted Date: 2024-06-25

Last Posted Date: 2025-01-03

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 148

Registration Number: NCT06474468

Locations: 🇨🇳
Affiliated Cancer Hospital of Shandong First Medical University, Jinan, Shandong, China

A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

Phase 1

Not yet recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: SHR-9839 ；SHR-A2009
Drug: SHR-9839 ； pemetrexed ；carboplatin
Drug: SHR-9839 ； Almonertinib
Drug: SHR-9839 ； SHR-A1921

First Posted Date: 2024-06-25

Last Posted Date: 2024-06-25

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 156

Registration Number: NCT06474455

Locations: 🇨🇳
HeNan CANCER HOSPITAL, Zhenzhou, Henan, China
🇨🇳
Zhejiang Cancer Hospital, Zhejiang, HangZhou, China

Phase Ib/II Study of HRS2398 in Combination With Adebrelimab in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: HRS2398
Drug: Adebrelimab

First Posted Date: 2024-06-03

Last Posted Date: 2024-07-05

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 88

Registration Number: NCT06439589

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

The Trial of SHR6508 in Secondary Hyperparathyroidism

Phase 3

Active, not recruiting

Conditions: Secondary Hyperparathyroidism

Interventions: Drug: Cinacalcet plus intravenous placebo
Drug: SHR6508 plus oral placebo tablets

First Posted Date: 2024-05-30

Last Posted Date: 2025-05-04

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 498

Registration Number: NCT06434961

Locations: 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China

A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: SHR-A2102 ; Adebrelimab injection
Drug: SHR-A2102

First Posted Date: 2024-05-16

Last Posted Date: 2024-12-31

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 80

Registration Number: NCT06417554

Locations: 🇨🇳
Peking University Cancer Hospital, Beijing, Beijing, China

SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor

Phase 1

Recruiting

Conditions: Cldn18.2-positive Advanced Solid Tumor

Interventions: Drug: SHR-A1904; Adebrelimab
Drug: SHR-A1904; CAPOX; Adebrelimab

First Posted Date: 2024-04-05

Last Posted Date: 2024-08-09

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 924

Registration Number: NCT06350006

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Investigating the Safety and Efficacy of SHR6508 Injection in the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients : A Multicenter, Long-term Clinical Trial

Phase 2

Active, not recruiting

Conditions: Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis

Interventions: Drug: SHR6508

First Posted Date: 2024-02-01

Last Posted Date: 2024-07-10

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 303

Registration Number: NCT06236295

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China

Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients

Phase 2

Recruiting

Conditions: Alzheimer's Disease

Interventions: Drug: SHR-1707
Drug: SHR-1707 placebo

First Posted Date: 2024-01-10

Last Posted Date: 2024-04-09

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 45

Registration Number: NCT06199037

Locations: 🇨🇳
The First Affiliated hospital of USTC, Hefei, Anhui, China

A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Phase 1

Recruiting

Conditions: Intermediate and High-risk Non-muscle Invasive Bladder Cancer

Interventions: Drug: SHR-2005

First Posted Date: 2023-10-31

Last Posted Date: 2024-12-03

Lead Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Target Recruit Count: 170

Registration Number: NCT06108492

Locations: 🇨🇳
Fudan University Zhongshan Hospital, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy